Tetracosactide
The synthetic ACTH fragment behind the standard test of adrenal function
Tetracosactide is the first 24 amino acids of ACTH, made synthetically, which is all the hormone needs to stimulate the adrenal glands. In the US, as Cortrosyn, it is the standard diagnostic test for adrenal insufficiency; outside the US a long-acting depot form treats infantile spasms.
Manufacturer's recommended dosing (FDA label): 0.25 mg, Single dose, Intravenous or intramuscular Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Adrenocorticotropic hormone (ACTH) is made by the pituitary gland and tells the adrenal glands to produce cortisol. Its activity sits in the first part of the molecule: the Cortrosyn label notes that amino acids 1 to 20 are the minimum needed for full activity, and that shortening the chain further quickly destroys it. Tetracosactide, also called cosyntropin, is a synthetic copy of the first 24 amino acids, and 0.25 mg stimulates the adrenal cortex as fully as 25 units of natural ACTH.
Its main use in the US is diagnostic. In the short stimulation test, blood cortisol is measured before an injection and exactly 30 and 60 minutes after; a weak rise points to adrenal insufficiency. Researchers have tested simpler ways to give it: a nasal spray with chitosan produced plasma cortisol at 60 minutes equivalent to the standard intravenous test, and in people on haemodialysis the test gave equivalent results during a dialysis session.
How accurate is the test? A 2016 systematic review of 30 studies (1,209 adults, 228 children) found the standard high-dose and the low-dose 1 µg versions about equally accurate for secondary adrenal insufficiency, the kind caused by the pituitary: both are good at ruling the diagnosis in and weaker at ruling it out. For primary adrenal failure, the high-dose test's sensitivity was about 92%. In practice the test is often requested without a clear question; a 2024 Queensland audit found the suspected cause unclear in 46% of requests.
Outside the US, a long-acting depot form treats infantile spasms, a severe epilepsy of babies; in a large analysis it stopped spasms about as often as high-dose prednisolone. The Cortrosyn label warns of hypersensitivity reactions and diagnostic inaccuracies, an audit found adverse events in about 6% of tests, and tetracosactide is named on WADA's Prohibited List. In the earlier UK Infantile Spasms Study, 76% of infants given the depot were free of spasms at two weeks, against 54% on vigabatrin.
Its other uses are mostly outside routine care. In the US, a 2022 randomised trial in 34 children with infantile spasms found the cosyntropin injectable suspension resolved spasms and the abnormal EEG by day 14 in 75% against 11% on vigabatrin, but the trial was underpowered. Anaesthetists have tried it to prevent headache after an accidental dural puncture during an epidural; in 234 deliveries, headache rates were 60% with it and 64% without, no meaningful difference. Given to treat an established headache after childbirth, a single dose did not reduce the need for a blood patch, and a 2025 trial was stopped for futility. Its benefit in hospitalised rheumatoid arthritis faded within three months, while as an antiemetic with cisplatin it matched dexamethasone. In eight trained cyclists a single injection did not improve time-trial performance or perceived exertion, and the urinary hormones measured did not change, which makes misuse hard to detect. A small sensitivity analysis from an Italian trial in rescue heart surgery reported fewer deaths after a 10 mg bolus, a result its authors say needs larger studies.
Most new work on tetracosactide is about getting the test right rather than the drug itself. In children, a 1 µg test read at 40 minutes missed fewer cases of central adrenal insufficiency than the traditional 60-minute sample, while for non-classical congenital adrenal hyperplasia the 60-minute 17-hydroxyprogesterone was the one that mattered. Newer cortisol assays read lower than older ones, so the classic 18 µg/dL pass mark now over-calls failures; one study put the stimulated threshold at 14.6 µg/dL and found a morning cortisol above 11.1 µg/dL made the test unnecessary. After removing one adrenal, testing helped mainly when next-morning cortisol fell between 5 and 10 µg/dL, and in primary aldosteronism a continuous infusion during adrenal vein sampling gave reliable results.
Mechanism of Action
Tetracosactide is the active front end of ACTH, so it does what ACTH does: tells the adrenal glands to make cortisol.
Melanocortin-2 receptor
It activates the ACTH receptor on adrenal cortex cells, raising cortisol within minutes; the first 20 amino acids carry full activity, according to the Cortrosyn label.
The stimulation test
A healthy adrenal raises cortisol after the injection; a weak rise points to adrenal insufficiency, and the test is better at confirming than excluding pituitary causes.
Infantile spasms
The long-acting depot form is used outside the US for infantile spasms; how ACTH stops them is not fully established.
Sport
Corticotrophins are prohibited in sport; tetracosactide is named on WADA's Prohibited List.
Published Research
The studies behind tetracosactide, read from their PubMed abstracts.
Depot vs prednisolone for infantile spasms
Among 126 infants in a prospective analysis embedded in the ICISS trial, spasms had stopped on days 13 to 14 in 76% on tetracosactide depot and 67% on prednisolone, not a significant difference; development scores and later epilepsy rates also did not differ significantly.
How the short Synacthen test is used
Among 363 patients tested in Queensland public hospitals in 2020, the suspected cause of adrenal insufficiency was unclear in 46% of requests, morning cortisol was checked first in only 69%, more than one in six tests could have been avoided, and 6.1% had a documented adverse event.
Cosyntropin vs vigabatrin, randomised
In an underpowered trial of 34 children with new infantile spasms, spasms and the abnormal EEG resolved by day 14 in 75% on cosyntropin injectable suspension, 11% on vigabatrin and 38% on both. Adverse events occurred in 86% overall, with no difference between arms.
No benefit for post-dural puncture headache
In 234 deliveries complicated by accidental dural puncture, headache occurred in 60% of patients given prophylactic cosyntropin and 64% of those not given it, a difference that was not significant; epidural blood patch use also did not differ.
A nasal stimulation test
Nasal tetracosactide formulated with chitosan had a bioavailability of 14.3%, and 500 µg produced plasma cortisol at 60 minutes not significantly different from the standard 250 µg intravenous test; salivary cortisol and cortisone offered a needle-free measure, and children responded like adults.
Testing during haemodialysis
In 28 patients on chronic haemodialysis, cortisol concentrations 30 and 60 minutes after standard- and low-dose Synacthen were equivalent whether the test was done before or during dialysis, so the test can be run during a session; in 10 of 56 low-dose tests cortisol peaked by 20 minutes.
Testing the adrenal after removing one
In 298 patients tested on the day after unilateral adrenalectomy, the cosyntropin test was always normal when morning cortisol exceeded 10 µg/dL; between 5 and 10 µg/dL it was abnormal in 38% of those with mild autonomous cortisol secretion and 12% of those with non-secreting tumours, so the authors suggest testing only in that middle band.
Best timing for the 1 µg test in children
In 646 low-dose (1 µg) tests in children with suspected central adrenal insufficiency, cortisol at 40 minutes gave significantly fewer false negatives than at 60 minutes, making it the most reliable single sample.
Morning cortisol with newer assays
In 95 adults evaluated for adrenal insufficiency, a morning cortisol of 11.1 µg/dL on a newer immunoassay predicted a normal 60-minute stimulated result (14.6 µg/dL or more) with 93% specificity; the old 18 µg/dL cut-off would have produced 17% false positives.
17-OHP timing in non-classical CAH
In 150 children tested for non-classical congenital adrenal hyperplasia with the standard-dose test, the 60-minute 17-hydroxyprogesterone caught three diagnoses that the 30-minute value missed, and no case was found only at 30 minutes.
Continuous infusion during adrenal vein sampling
In 88 patients with primary aldosteronism, adrenal vein sampling under a continuous cosyntropin infusion was technically adequate in 89%, showed one-sided disease in 62%, and 42 of 43 operated patients responded clinically.
UKISS: hormones beat vigabatrin at two weeks
In the UK Infantile Spasms Study, 107 infants were randomised to vigabatrin or hormonal treatment; spasms had stopped on days 13-14 in 76% given intramuscular tetracosactide depot (0.5 mg on alternate days) and 70% given prednisolone, 73% of the hormonal group overall, against 54% on vigabatrin, with adverse events in just over half of each group.
Rescue heart surgery: a small sensitivity analysis
In a sensitivity analysis of 100 patients from the STOPSHOCK phase 3 trial needing rescue cardiovascular surgery, a single 10 mg intravenous bolus before surgery was associated with lower 30-day mortality (0 against 8 deaths) and fewer transfusion episodes (odds ratio 0.32); the authors say larger studies are needed.
Headache after childbirth: stopped for futility
In a double-blind trial in postpartum women with post-dural puncture headache, a single 1 mg intravenous dose of tetracosactide did not reduce the need for an epidural blood patch (91% against 86% on placebo) or headache intensity or duration, and the trial was stopped for futility after 44 patients.
Chemotherapy nausea: matched dexamethasone
In a double-blind crossover trial in 33 patients receiving cisplatin chemotherapy, intravenous tetracosactide (2 mg) and dexamethasone (20 mg), each added to metoclopramide, diphenhydramine and clorazepate, did not differ in antiemetic efficacy or side effects.
Rheumatoid arthritis: a short-lived benefit
In 36 inpatients with active rheumatoid arthritis randomised to two injections of Synacthen Depot (0.5 mg on alternate days) or saline, more met the ACR 50% response at discharge (52.6% against 17.6%), but no single disease measure differed and the benefit was gone by three months, with a suggestion of rebound worsening.
No boost for trained cyclists
In a placebo-controlled crossover study in eight trained cyclists, a single 0.25 mg intramuscular injection of Synacthen did not change 20-km time-trial performance or perceived exertion that day or the next, and the urinary hormones measured did not change, which the authors note makes misuse hard to detect.
Accuracy of ACTH stimulation tests
Across 30 studies in secondary adrenal insufficiency, high- and low-dose tests had similar accuracy, good for ruling in (positive likelihood ratios 5.9 to 43.5) and weaker for ruling out; high-dose sensitivity for primary insufficiency was 92% in five studies.
Dosing Data
Tetracosactide (cosyntropin) is used in the US as a single diagnostic injection; doses below are the label's test doses.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Cortrosyn (cosyntropin injection): For injection: 0.25 mg of cosyntropin as a lyophilized powder in single-dose vial for reconstitution. Forms the label lists: single-dose vials.
Source: Cortrosyn (cosyntropin injection) label, section 3 (DailyMed version 9, effective January 30, 2025).
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Tetracosactide is prepared and given by clinical staff, in a hospital or clinic, as a test.
Its US label uses it only as a diagnostic agent when screening for adrenal insufficiency, injected with timed cortisol samples.
Source: Cortrosyn (cosyntropin injection) label, section 1 (DailyMed version 9, effective January 30, 2025).
Storage before and after mixing
Before mixing or first use: “Store at 20º to 25ºC (68º to 77ºF); excursions permitted between 15° to 30°C (59° to 86°F).”
After mixing or first use: “Any unused portion should be discarded.” “If the CORTROSYN reconstituted solution is not used immediately, discard the unused CORTROSYN reconstituted solution.”
Source: Cortrosyn (cosyntropin injection) label, sections 16 and 2 (DailyMed version 9, effective January 30, 2025).
How it is taken
As the approved label gives it: Intravenous or intramuscular (Single dose; Label: stimulation test, adults and children 2+).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Label: stimulation test, adults and children 2+: Once; Label: stimulation test, birth to under 2 years: Once.
When effects appear: unknown; no source on this page gives a time to effect for Tetracosactide. Results reported in the studies are under Published Research.
Source: Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Adverse events in about 6% of short Synacthen tests in one hospital audit; Serious reactions, most often infection, during hormonal treatment of infantile spasms. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Tetracosactide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- glucocorticoids and spironolactone: may falsely raise plasma cortisol; stop on the day of testing (longer for long-acting glucocorticoids)
- oestrogen-containing drugs: may raise total plasma cortisol; stop 4 to 6 weeks before testing
Every peptide's record, with its source: the interaction matrix.
Source: Amphastar. CORTROSYN (cosyntropin) for injection, US prescribing information, section 7. DailyMed version effective January 30, 2025, read October 5, 2026.
Checking what you bought
Unknown: no published independent test of Tetracosactide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Cortrosyn (cosyntropin), NDA 016750, on April 22, 1970, now held by Amphastar, as a diagnostic agent with other tests in screening for adrenocortical insufficiency in adults and children). Sport: Prohibited at all times (S2.2.2).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Cortrosyn label (DailyMed, effective January 30, 2025).
Legal Status
Tetracosactide is approved in the US as a diagnostic agent.
Frequently Asked Questions
?What is the cosyntropin test?
A blood test of adrenal function: cortisol is measured before an injection of cosyntropin and 30 and 60 minutes after. A weak rise suggests adrenal insufficiency.
?Is tetracosactide the same as ACTH?
It is the first 24 of ACTH's 39 amino acids, made synthetically, which carry the hormone's full activity on the adrenal glands.
?Is tetracosactide banned in sport?
Yes. WADA's Prohibited List names it under corticotrophins and their releasing factors.
?What is the low-dose ACTH test?
A version using about 1 µg instead of 0.25 mg; a 2016 review found it about as accurate as the standard test for pituitary-related adrenal insufficiency.
?Is tetracosactide banned in sport?
Yes. Corticotrophins are prohibited, and tetracosactide is named on WADA's Prohibited List.
?Why must blood be drawn at exactly 30 and 60 minutes?
The label's interpretation depends on cortisol at those times; samples drawn late or early can make a healthy adrenal look weak or a weak one look healthy.
?Is the depot form available in the US?
The long-acting depot form used for infantile spasms is marketed in other countries. In the US, a cosyntropin injectable suspension has been tested in a small randomised trial, but the approved product, Cortrosyn, is labelled for the diagnostic test.
?What is the difference between tetracosactide and ACTH?
Natural ACTH has 39 amino acids; tetracosactide is the first 24, which carry its activity. According to the Cortrosyn label, 0.25 mg stimulates the adrenal cortex as fully as 25 units of natural ACTH.
References
- [fda] US FDA, Drugs@FDA (openFDA): CORTROSYN (cosyntropin), NDA 016750, original approval April 22, 1970, prescription; cosyntropin ANDA 202147. Read October 3, 2026.
- [fda-pi] FDA. Cortrosyn (cosyntropin) US prescribing information (DailyMed set 746856e9-3930-4f6a-b8e6-a03845d6dd0b, version 9, effective January 30, 2025). Read October 3, 2026.
- [pubmed] Osborne JP, et al. "Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials." Eur J Paediatr Neurol, 2023;42:110-116. PMID: 36621063.
- [pubmed] Wootton E, et al. "A retrospective review of the short Synacthen test in Queensland hospitals." Intern Med J, 2024;54(9):1515-1522. PMID: 38660891.
- [pubmed] Knupp KG, et al. "Comparison of Cosyntropin, Vigabatrin, and Combination Therapy in New-Onset Infantile Spasms in a Prospective Randomized Trial." J Child Neurol, 2022;37(3):186-193. PMID: 35044272.
- [pubmed] Ellis E, et al. "Prophylactic cosyntropin after unintentional dural puncture and incidence of post-dural puncture headache and epidural blood patch use: A retrospective cohort study (2019-2022)." Int J Obstet Anesth, 2024;60:104262. PMID: 39306572.
- [pubmed] Elder CJ, et al. "Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test." J Clin Endocrinol Metab, 2020;105(8). PMID: 32593173.
- [pubmed] Nickler M, et al. "Performance of synacthen test in chronic hemodialysis patients." BMC Nephrol, 2023;24(1):330. PMID: 37936106.
- [pubmed] Ospina NS, et al. "ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis." J Clin Endocrinol Metab, 2016;101(2):427-34. PMID: 26649617.
- [pubmed] Akkus D, et al. "The utility of cosyntropin stimulation test in the assessment of adrenal function after unilateral adrenalectomy." Surgery, 2026:110585. PMID: 42816228.
- [pubmed] Gürpınar Tosun B, et al. "The 40(th) Minute Cortisol Measurement is the Key Time-Point in the Low-Dose Synacthen Stimulation Test: A Large, Assay-Specific Pediatric Validation Study." J Clin Res Pediatr Endocrinol, 2026;18(3):394-401. PMID: 42043277.
- [pubmed] Shrestha E, et al. "Newer Generation Immunoassays in Screening for Adrenal Insufficiency: Comparison of Baseline Morning Cortisol Levels With Cosyntropin Stimulation Testing." AACE Endocrinol Diabetes, 2026;13(3):533-536. PMID: 42221401.
- [pubmed] Çiftci N, et al. "Timing of 17-hydroxyprogesterone measurement during the standard-dose Synacthen test in pediatric patients evaluated for non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency." Arch Endocrinol Metab, 2026;70(5):e260081. PMID: 42536762.
- [pubmed] Liu L, et al. "Adrenal vein sampling with continuous infusion of cosyntropin for identifying surgically curable cases of primary aldosteronism." Clin Imaging, 2026;129:110664. PMID: 41202648.
- [pubmed] Lux AL, et al. "The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial." Lancet, 2004;364(9447):1773-8. PMID: 15541450.
- [pubmed] Noera G, et al. "Effect of early administration of tetracosactide on mortality and host response in critically ill patients requiring rescue surgery: a sensitivity analysis of the STOPSHOCK phase 3 randomized controlled trial." Mil Med Res, 2024;11(1):56. PMID: 39160574.
- [pubmed] Dziadzko M, et al. "No effect of tetracosactide for treatment of postdural puncture headaches in parturient women: a double-blind randomised controlled clinical trial." Br J Anaesth, 2025;135(1):148-154. PMID: 40393818.
- [pubmed] Culine S, et al. "[A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin]." Bull Cancer, 1989;76(6):583-9. PMID: 2673437.
- [pubmed] Taylor WJ, et al. "Inpatient treatment of rheumatoid arthritis with synacthen depot: a double blind placebo controlled trial with 6 month followup." J Rheumatol, 1999;26(12):2544-50. PMID: 10606361.
- [pubmed] Baume N, et al. "No variation of physical performance and perceived exertion after adrenal gland stimulation by synthetic ACTH (Synacthen) in cyclists." Eur J Appl Physiol, 2008;104(4):589-600. PMID: 18584198.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.